Richard Norton's death was triggered by a peptide injection, coroner finds

Australian actor and martial artist Richard Norton died in March 2025 after an injection of the peptide blend CJC1295 and ipamorelin set off anaphylaxis and then cardiac arrest, a Victorian coroner has found. In a finding dated October 28, 2026, Coroner David Ryan also recommended that Australia's Therapeutic Goods Administration consider further restrictions on such peptides, such as a Schedule 10 listing that could ban their human use subject to specific exceptions such as clinical trials [1].

Reader offer · IQON Labs

Buy 1, Get 1 20% Off

Pick any two research compounds. Take 20% off the lower priced one.

20% OFF

Applied automatically at checkout, no code needed

Claim my 20% off →

In every pair, the lower priced item is 20% off after other discounts; accessories excluded. For research use only.

IQON Labs publishes a separate research use only catalog. Nothing in this report is a suggestion to obtain or use any peptide, and no research reagent is a substitute for medical care.

Nine days from prescription to collapse

Norton, 75, had asthma, osteoarthritis and two previous shoulder reconstructions when he consulted Dr Jerzy Muchnicki in early 2025. He told Muchnicki another practitioner had previously prescribed him peptides for fatigue, slow physical recovery, shoulder pain and loss of lean muscle mass [1][3].

Muchnicki ordered blood tests and a CT scan of Norton's coronary artery calcium. On March 15, Norton signed an informed consent form for peptide therapy that listed anaphylaxis among the risks of CJC1295 and ipamorelin. On March 19, Muchnicki prescribed the blend, made by a licensed compounding pharmacy in Queensland [1].

On March 25, Norton told Muchnicki he was feeling good and that the treatment was improving his symptoms. Three days later, at about 4pm on March 28, he spoke with a nurse at Muchnicki's clinic, saying he had dropped and broken a vial and needed a replacement. He also told the nurse that he had been taking double the prescribed dose. The nurse told him to return to the prescribed dose from the following week, and Muchnicki, reached by the nurse over the phone, authorised the replacement [1].

Hospital records later described a pattern that had been building since the first injection: local redness and swelling at first, then whole-body flushing over the last few days. On the morning of March 28 he had flushing, chest tightness and shortness of breath that eased after he used his asthma reliever [1].

At about 9pm that night he injected again, his second dose of the day. He told his wife Judy he felt hot and flushed, then collapsed. Her GP called emergency services at 9.10pm and she began CPR. Paramedics arrived at about 9.22pm to find him in cardiac arrest, restarted his heart at 9.55pm and took him to the Alfred Hospital. He developed ischaemic bowel, was judged unsuitable for further intervention, and died on March 30 at 10.17am [1].

What the autopsy found

At the Alfred, clinicians recorded raised tryptase and troponin levels and assessed that Norton had likely suffered a cardiac arrest caused by anaphylaxis from the peptide injection [1].

Forensic pathologist Daniel Hussey of the Victorian Institute of Forensic Medicine found evidence of anaphylaxis at autopsy. Anaphylaxis is a severe allergic reaction in which immune cells called mast cells release their contents into surrounding tissue, which can swell the airway and drop blood pressure far enough to stop the heart. Hussey favoured the peptide injections as a possible cause because the allergic symptoms began after Norton started the therapy and escalated before his collapse [1].

The autopsy also found hypertrophic cardiomyopathy, a thickening of the heart muscle that raises the risk of fatal rhythm problems, and Hussey said both it and Norton's asthma could have contributed. Post-mortem toxicology could not detect the specific peptides. The drugs it did find matched the emergency treatment he received, such as midazolam, amiodarone and atropine. The medical cause of death was recorded as complications of an out-of-hospital cardiac arrest due to anaphylaxis, with asthma and hypertrophic cardiomyopathy as contributing conditions [1].

Coroners in Victoria decide facts on the balance of probabilities and do not determine criminal or civil liability. On that standard, Ryan wrote: "I am satisfied that Richard's death was triggered by his injection of the peptide CJC1295/Ipamorelin." His next sentence adds: "Richard had been taking amounts of the medication in excess of the dose prescribed by his medical practitioner" [1].

Why the prescribing doctor was cautioned

A separate complaint went to the Australian Health Practitioner Regulation Agency, known as Ahpra, and the Medical Board of Australia commissioned an expert report from Clinical Professor Alistair Vickery. He described CJC1295 and ipamorelin as experimental, with no approved therapeutic use in Australia and no quality studies of safety or benefit, and listed rare allergic reactions including anaphylaxis among its likely adverse effects [1].

Vickery judged Muchnicki's overall clinical care to be at the standard reasonably expected, given the consent obtained and Norton's prior use. He found two failures: the clinical notes were "sparse, inadequate and perfunctory", and Muchnicki should have spoken to Norton directly before approving more of the same medicine on March 28, when a nurse had just recorded that he was taking twice the prescribed amount [1].

In a decision dated July 16, 2026, the board found that Muchnicki's practice "is or may be unsatisfactory" on both points. It decided no regulatory action was warranted over the clinical care itself, but cautioned him and placed conditions on his registration requiring one-on-one education in record keeping followed by an audit. Muchnicki accepted the criticism, apologised for his errors, expressed sorrow for the impact on Norton's family and told the board he would no longer prescribe peptides unless clinical evidence clearly supported them [1].

What the coroner wants the TGA to consider

In Australia, CJC1295 and ipamorelin are Schedule 4 prescription-only medicines, but they are not on the Australian Register of Therapeutic Goods, which makes them unapproved goods that the TGA has never evaluated for quality, safety or efficacy. Doctors can reach them through routes such as the Authorised Prescriber Scheme, and are generally expected to have considered registered treatments first. The TGA told the court it had received six reports of anaphylaxis or hypersensitivity in people using CJC1295 and ipamorelin or other unapproved peptides, including three cases of anaphylaxis with CJC1295 and ipamorelin, not counting Norton's [1].

Ryan was not persuaded that such products should remain prescribable. "It is not clear to me how their safe use can be clinically indicated," he wrote, given uncertain benefits and risks "as yet not fully known" [1]. He recommended that the TGA review their benefits and risks and consider moving them to Schedule 10, the category for "substances of such danger to health as to warrant prohibition of supply and use", with room for clinical trials and other research to continue [1].

Ryan directed that the finding go to the TGA, Ahpra, Alfred Health, Muchnicki and Norton's family. A recommendation is not an order: any scheduling change would be for the TGA and the national scheduling process to decide [1].

Thirteen anaphylaxis cases in Victoria since July 2025

The finding arrived a day after Victoria's Department of Health issued a health advisory on October 27. Since July 2025, the state has received 13 notifications of anaphylaxis associated with unapproved peptides, five of them in September 2026 and two more in October. Before July 2025, only one such case had been recorded since anaphylaxis notifications began in 2018 [2].

Twelve of the 13 people had never had anaphylaxis before. The advisory warns that a reaction can follow the first dose or come after several uneventful ones, and that the contents of unapproved products, including the substance, its concentration and any contaminants, are unknown. Non-sterile manufacturing raises the risk of infection and allergic reactions [2].

Norton's case sits awkwardly beside that warning. The advisory is aimed mainly at products used without a prescription, while Norton's blend was prescribed, made by a licensed compounding pharmacy and taken after written consent that named anaphylaxis as a risk [1][2]. Even inside that system, the prescription went through as an unapproved medicine with no regulator-evaluated safety data behind it.

Health practitioners now have new national guidance to weigh. Published by Ahpra in September 2026, it says off-label, unapproved or compounded medicines should be prescribed only where there is sufficient evidence, a clear indication, or where other treatments have not worked or are unsuitable [1][4].

Where these peptides stand in the United States

The US Food and Drug Administration has flagged both compounds in its compounding safety lists. Ipamorelin acetate has been in category 2 of FDA's interim policy for outsourcing facilities since September 29, 2023, which marks bulk substances FDA says may present significant safety risks. FDA cites the risk of immune reactions from aggregation or peptide-related impurities, and a published study that recorded serious adverse events, including death, when ipamorelin was given intravenously for gastric motility [5].

CJC-1295 sits on the same page's list of nominations that were later withdrawn. FDA's note on it says compounded CJC-1295 may carry an immunogenicity risk for some routes of administration and that FDA has identified serious adverse events including increased heart rate and a systemic vasodilatory reaction [5]. Immunogenicity, the tendency of a peptide product to provoke the immune system, is the same family of risk at the centre of the Norton finding. Our explainer on anti-drug antibodies covers how researchers measure it.

What happens next

The next document to watch is the TGA's response. The coroner has asked it to look again at a group of peptides that Australian law currently allows doctors to prescribe, on the strength of a death in which the prescription, the pharmacy and the consent form were all in place [1].

For Victoria's health department, the measure is whether anaphylaxis notifications linked to peptides keep rising after a month in which it recorded five [2]. For anyone following the debate elsewhere, the product in this case did not come from a black-market supplier. It came through a doctor's prescription and a licensed compounding pharmacy, although the coroner also found Norton had been taking more than the prescribed dose [1].

Frequently asked questions

What did Richard Norton die from?

The coroner recorded complications of an out-of-hospital cardiac arrest caused by anaphylaxis, with asthma and hypertrophic cardiomyopathy as contributing conditions. He found the anaphylaxis was triggered by an injection of a CJC1295 and ipamorelin blend on March 28, 2025. Norton died at the Alfred Hospital in Melbourne on March 30, 2025.

[1]

Was the peptide prescribed by a doctor?

Yes. Dr Jerzy Muchnicki prescribed the blend on March 19, 2025, and it was made by a licensed compounding pharmacy in Queensland. Norton told a nurse on March 28 that he had been taking double the prescribed dose.

[1]

Were other substances involved?

Post-mortem toxicology found only drugs consistent with the emergency treatment Norton received and could not detect the specific peptides. After his death, his wife gave police his medication containers, including an unsealed pouch with a vial of CJC1295 and ipamorelin and a sealed pouch holding an unused vial of another peptide Muchnicki had prescribed on March 28.

[1]

Has Australia banned CJC1295 and ipamorelin?

No. The coroner recommended that the Therapeutic Goods Administration review the peptides and consider listing them in Schedule 10, which would prohibit supply and use outside exceptions such as clinical trials. The finding was sent to the TGA, and any scheduling change is for the regulator to decide.

[1]

How many peptide anaphylaxis cases has Victoria recorded?

Victoria's Department of Health reported 13 anaphylaxis notifications associated with unapproved peptides since July 2025, including five in September 2026 and two in October up to its October 27 advisory. Twelve were first episodes of anaphylaxis.

[2]